The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
Open accessAbstract
OBJECTIVES: Assess the efficacy and safety of tocilizumab in patients with systemic sclerosis (SSc) in a phase II study. METHODS: Patients with SSc were treated for 48 weeks in an open-label extension phase of the faSScinate study with weekly 162 mg subcutaneous tocilizumab. Exploratory end points included modified Rodnan Skin Score (mRSS) and per cent predicted forced vital capacity (%pFVC) through week 96. RESULTS: Overall, 24/44 (55%) placebo-tocilizumab and 27/43 (63%) continuous-tocilizumab patients completed week 96. Observed mean (SD (95% CI)) change from baseline in mRSS was -3.1 (6.3 (-5.4 to -0.9)) for placebo and -5.6 (9.1 (-8.9 to-2.4)) for tocilizumab at week 48 and -9.4 (5.6 (-8.9 to -2.4)) for placebo-tocilizumab and -9.1 (8.7 (-12.5 to -5.6)) for continuous-tocilizumab at week 96. Of patients who completed week 96, any decline in %pFVC was observed for 10/24 (42% (95% CI 22% to 63%)) placebo-tocilizumab and 12/26 (46% (95% CI 27% to 67%)) continuous-tocilizumab patients in the open-label period; no patients had >10% absolute decline in %pFVC. Serious infection rates/100 patient-years (95% CI) were 10.9 (3.0 to 27.9) with placebo and 34.8 (18.0 to 60.8) with tocilizumab during the double-blind period by week 48 and 19.6 (7.2 to 42.7) with placebo-tocilizumab and 0.0 (0.0 to 12.2) with continuous-tocilizumab during the open-label period. CONCLUSIONS: Skin score improvement and FVC stabilisation in the double-blind period were observed in placebo-treated patients who transitioned to tocilizumab and were maintained in the open-label period. Safety data indicated increased serious infections in patients with SSc but no new safety signals with tocilizumab. TRIAL REGISTRATION NUMBER: NCT01532869; Results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In systemic Th17-related autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, and systemic sclerosis, treatment with biologics that inhibit IL-6 is an effective or promising therapy (80–82).”
From T H 17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity (2020) · cites this paper as [81]
In the citing paper
“In an initial phase 2 double-blind, placebo controlled study tocilizumab did not significant reduce skin thickening (189), but the open label extension phase of this study did show encouraging protective effects on skin thickening and loss of forced vital capacity in SSc patients (190).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [190]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
van den Hoogen, F., Khanna, D., Fransen, J., Johnson, S. R., Baron, M., Tyndall, A., Matucci-Cerinic, M., Naden, R. P., Medsger, T. A., Carreira, P. E., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204424 · Cited by 2,886
Self-citationDenton, C. P., & Khanna, D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30933-9 · Cited by 2,212
Self-citationCyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationChanges in causes of death in systemic sclerosis, 1972–2002
Steen, V. D., & Medsger, T. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066068 · Cited by 1,528
Self-citationTashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,078
Self-citationvan Laar, J. M., Farge, D., Sont, J. K., Naraghi, K., Marjanovic, Z., Larghero, J., Schuerwegh, A. J., Marijt, E. W. A., Vonk, M. C., Schattenberg, A. V., et al. (2014) · JAMA · doi:10.1001/jama.2014.6368 · Cited by 766
Hoyles, R. K., Ellis, R. W., Wellsbury, J., Lees, B., Newlands, P., Goh, N. S. L., Roberts, C., Desai, S., Herrick, A. L., McHugh, N. J., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22204 · Cited by 732
Self-citationKhanna, D., Denton, C. P., Jahreis, A., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00232-4 · Cited by 683
Self-citationKowal-Bielecka, O., Landewé, R., Avouac, J., Chwiesko, S., Miniati, I., Czirjak, L., Clements, P., Denton, C., Farge, D., Fligelstone, K., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.096677 · Cited by 619
Self-citation
Research works printed but not linked: 1
- Namas, 2017, Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: Post-hoc analyses from the Scleroderma Lung Study I and II, Arthritis Care Res
Cited by
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
The Role of IL-6 in Skin Fibrosis and Cutaneous Wound Healing
Johnson, B. Z., Stevenson, A. W., Prêle, C. M., Fear, M. W., & Wood, F. M. (2020) · Biomedicines · doi:10.3390/biomedicines8050101 · Cited by 529
“The faSScinate phase II randomized controlled trial compared the effects of subcutaneous tocilizumab injections on skin fibrosis, compared to controls [93].”
BackgroundCOVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
Sarzi-Puttini, P., Giorgi, V., Sirotti, S., Marotto, D., Ardizzone, S., Rizzardini, G., Antinori, S., & Galli, M. (2020) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/xcdary · Cited by 466
“The off-label use of tocilizumab in the interstitial lung disease (ILD) caused by rheumatological diseases has been widely studied and is approved in many countries (54-58).”
BackgroundSystemic sclerosis-associated interstitial lung disease
Perelas, A., Silver, R. M., Arrossi, A. V., & Highland, K. B. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30480-1 · Cited by 422
Hoffmann-Vold, A.-M., Maher, T. M., Philpot, E. E., Ashrafzadeh, A., Barake, R., Barsotti, S., Bruni, C., Carducci, P., Carreira, P. E., Castellví, I., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30144-4 · Cited by 310
Metadata
- Authors
- Khanna, D., Denton, C. P., Lin, C. J. F., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., Allanore, Y., Pope, J. E., Riemekasten, G., Steen, V., Müller-Ladner, U., Spotswood, H., Burke, L., Siegel, J., Jahreis, A., & Furst, D. E.
- Affiliations
- University of Michigan (US)
- University College London (GB)
- Genentech (US)
- University of Utah (US)
- University of Liverpool (GB)
- Jewish General Hospital (CA)
- VA Palo Alto Health Care System (US)
- University of Tübingen (DE)
- UConn Health (US)
- Université Paris Descartes (FR)
- Western University (CA)
- Charité – Universitätsmedizin Berlin (DE)
- Georgetown University (US)
- Roche (United Kingdom) (GB)
- University of California, Los Angeles (US)
- Corresponding author
- Khanna, Dinesh
- ORCID
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 77
- Issue
- 2
- Pages
- 212-220
- ISSN
- 0003-4967 (ISSN-L)
- PMC
- PMC5867414
- OpenAlex
- W2766145635
- Cited by
- 265
- References
- 42
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 10 · 2023: 13 · 2022: 35 · 2021: 46 · 2020: 67 · 2019: 39 · 2018: 24
- FWCI
- 28.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- Locations
- Annals of the Rheumatic Diseases (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Roche
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- systemic sclerosis, tocilizumab, subcutaneous tocilizumab, IL-6 inhibition, modified Rodnan skin score, forced vital capacity, lung function decline, serious infections, treatment safety, open-label extension, skin involvement, pulmonary involvement, disease-modifying therapy, treatment discontinuation
- MeSH terms
- Adult, Aged, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Scleroderma, Systemic, Severity of Illness Index, Skin, Vital Capacity, Treatment Outcome, Antirheumatic Agents, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). https://app.cochat.ai/papers/10.1136/annrheumdis-2017-211682
- The paper
- Khanna, D., Denton, C. P., Lin, C. J. F., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., Allanore, Y., Pope, J. E., Riemekasten, G., Steen, V., Müller-Ladner, U., Spotswood, H., Burke, L., Siegel, J., Jahreis, A., & Furst, D. E. (2018). Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2017-211682
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.